5 year returnS&P Biotech ETF down 18.3%.
CZO down 5.95%.
That's what a biotech bear market does.
CZO's base business has kept the company viable in this historic bear market for biotech.
Many small scap biotech stocks have been abandoned, are going bankrupt, or are being restructured now. This creates an opportunity for companies like CZO. CZO has been investigating reverse takeovers to list on NASDAQ. Of the many biotech companies that have been abandoned which one could add cash, revenue, pipeline, and build scale as CZO's pipeline reaches key strategic milestones from the 5X and 10X PGX scale-up and potential licensing deal, to the avenanthramide clinical trial results, to the year beta glucan fibrosis trial, to the wound healing clinical trials.